Related Experiment Video

Updated: Jun 28, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Glycogen synthase kinase-3 and cancer: good cop, bad cop?

Satish Patel1, Jim Woodgett

  • 1Samuel Lunenfeld Research Institute, Toronto, ON, Canada.

Cancer Cell
|November 4, 2008
PubMed

Insights

Inhibition of glycogen synthase kinase-3 (GSK-3) was thought to promote cancer. However, new research shows GSK-3 inhibition may selectively target certain leukemias, offering potential new cancer treatments.

Area of Science:

  • Biochemistry
  • Oncology
  • Molecular Biology

Background:

  • Glycogen synthase kinase-3 (GSK-3) is a pleiotropic protein kinase.
  • GSK-3 normally represses beta-catenin, a protein implicated in cancer.
  • Previous dogma suggested GSK-3 inhibition was procarcinogenic.

Purpose of the Study:

  • To investigate the role of GSK-3 inhibition in specific cancer types.
  • To explore the potential of GSK-3 inhibitors as targeted anticancer agents.

Main Methods:

  • The study by Wang et al. focused on specific leukemia models.
  • Experimental approaches likely involved molecular and cellular assays to assess GSK-3 activity and its effects on cancer cells.

Main Results:

  • Contrary to established dogma, GSK-3 inhibition demonstrated an anticancer effect in certain leukemias.
  • This suggests a context-dependent role for GSK-3 in oncogenesis.

Conclusions:

  • GSK-3 inhibition may serve as a selective anticancer strategy for specific leukemias.
  • Small-molecule GSK-3 inhibitors could be developed as novel therapeutic agents for these cancers.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...